Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients: A Propensity Score Matched Competing Risks Analysis

Objective: To investigate cancer- and noncancer-specific mortality following lobectomy by minimally invasive surgery (MIS) versus open thoracotomy in elderly patients with nonsmall cell lung cancer (NSCLC). Background: Two-thirds of patients with NSCLC are ≥65 years of age. As age increases, the risk of competing events, such as noncancer death, also increases. Methods: Elderly patients (≥65 yrs of age) who have undergone curative-intent lobectomy for stage I-III NSCLC without induction therapy (2002–2013) were included (n=1,303). Of those, 607 patients had undergone MIS and 696 had undergone thoracotomy. Propensity-score matching was performed to identify pairs of thoracotomy and MIS patients with comparable clinical characteristics (eg, year of surgery, comorbidities, and pulmonary function). Association between surgical approach (MIS vs thoracotomy) and lung cancer-specific and noncancer-specific cumulative incidence of death (CID) was analyzed using competing risks approach. Results: Following propensity score matching of patients who had undergone thoracotomy (n=338) versus MIS (n=338), MIS was associated with shorter length of stay (P
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research

Related Links:

Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Advanced Lung Non-Small Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Sta ge IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Intervention:   Drug: Fluorin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic;   Healthy Intervention:   Sponsor:   Indiana University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Lung Non-Small Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Sta ge IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8 Intervention:   Drug: Fluorin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic;   Healthy Intervention:   Sponsor:   Indiana University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
THURSDAY, Dec. 5, 2019 -- For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation, overall survival is longer for treatment with osimertinib rather than comparator tyrosine kinase inhibitors of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
THURSDAY, Dec. 5, 2019 -- There is considerable variation across counties in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC), according to a study published online Dec. 5 in CHEST. Helmneh M. Sineshaw, M.D.,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Authors: Huang L, Qiao G, Morse MA, Wang X, Zhou X, Wu J, Hobeika A, Ren J, Lyerly HK Abstract Adoptive T cell immunotherapy with cytokine-induced killer cells (CIKs) has been demonstrated to prolong the survival of patients with advanced non-small cell lung cancer (NSCLC). The aim of the present study was to evaluate whether the expansion of effector T cells and the decrease of regulatory T cells (Tregs) that occurred during the ex vivo generation of DC-CIKs were associated with improved clinical outcome in patients who received treatment. CIKs were generated ex vivo over a 28-day period from the peripheral blood ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Liao Y, Wang X, Zhong P, Yin G, Fan X, Huang C Abstract As a malignant tumor with poor prognosis, accurate and effective treatment of non-small cell lung cancer (NSCLC) is crucial. To predict overall survival in patients with stage II and III NSCLC, a nomogram was constructed using data from the Surveillance, Epidemiology and End Results database. Eligible patients with NSCLC with available clinical information diagnosed between January 1, 2010 and November 31, 2015 were selected from the database, and the data were randomly divided into a training set and a validation set. Univariate and multivariate Cox ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, the present study provides further understanding of the pathogenesis of LUSC, and reveals CCNB1, CEP55, FOXM1, MKI67 and TYMS as potential biomarkers or therapeutic targets. PMID: 31788059 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Minimally Invasive Surgery | Non-Small Cell Lung Cancer | Surgery | Thoracotomy